

SPARC/Sec/SE/2026-27/14

June 25, 2026

**National Stock Exchange of India Ltd.,**  
Exchange Plaza, 5th Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East), Mumbai – 400 051.

**BSE Limited,**  
Market Operations Dept.  
P. J. Towers,  
Dalal Street,  
Mumbai - 400 001.

*Scrip Symbol:* SPARC

*Scrip Code:* 532872

Dear Sir/ Madam,

**Sub: Intimation regarding Termination of License Agreement with CMS Bridging DMCC (CMS) under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

---

This is with reference to the License Agreement dated November 05, 2019 entered into with CMS Bridging DMCC (“CMS”), has been mutually terminated by the parties on June 25, 2026.

We would like to further inform that there is no material impact on the Company’s financial position, operations or other activities due to the termination of the agreement.

The disclosure required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR”) read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 for the above termination of License Agreement is provided in **Annexure A**.

This is for your information and dissemination purpose.

Yours faithfully,

For **Sun Pharma Advanced Research Company Ltd.**

**Kajal Damania**  
**Company Secretary and Compliance Officer**

**Annexure A**

**Disclosure under Regulation 30 of SEBI LODR read with Sub para (5) of Para (B) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.**

a.	Name(s) of parties with whom the agreement is entered	CMS Bridging DMCC
b.	Purpose of entering into the agreement	The purpose of the License Agreement was to develop and commercialize multiple products i.e Xelpros™, Elepsia™, Taclantis™, PDP-716, SDN-037 in Mainland China, Hong Kong, Macao and Taiwan.
c.	Size of agreement	Not Applicable
d.	Shareholding, if any, in the entity with whom the agreement is executed	Nil
e.	Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc	Not Applicable
f.	Whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship	None of the parties are related to promoter/promoter group/ group companies in any manner.
g.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length	No
h.	In case of issuance of shares to the parties, details of issue price, class of shares issued	Not Applicable
i.	In case of loan agreements, details of lender/borrower, nature of the loan, total amount of loan granted/taken, total amount outstanding, date of	Not Applicable

	execution of the loan agreement/sanction letter, details of the security provided to the lenders / by the borrowers for such loan or in case outstanding loans lent to a party or borrowed from a party become material on a cumulative basis.	
j.	Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc	Not Applicable
k.	In case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s)	
	a) name of parties to the agreement;	CMS Bridging DMCC
	b) nature of the agreement;	Termination of Agreement
	c) date of execution of the agreement;	June 25, 2026
	d) details of amendment and impact thereof or reasons of termination and impact thereof.	The License Agreement with CMS has been terminated mutually and there is no material impact on the Company's financial position, operations or other activities due to the termination of the agreement.

**For Sun Pharma Advanced Research Company Ltd.**

**Kajal Damania**  
**Company Secretary and Compliance Officer**